Arvinas (ARVN) Insider Leslie Norwalk Buys 15,527 Shares

On June 24, 2026, Leslie Norwalk purchased 15,527 shares of Arvinas, Inc. (NasdaqGS: ARVN). The transaction, which was not part of a pre-planned trading program, adds to the insider activity at the biotechnology firm. Shares of Arvinas traded near $8.03 on Saturday.

Insider Buying and Selling at Arvinas, Inc.

Several insiders at Arvinas, Inc. were active on June 24, 2026. Leslie Norwalk acquired 15,527 shares, while other insiders like Bain Linda and Morrison Briggs also bought significant stakes. These transactions were executed without any pre-planned trading arrangement.

Other Institutional Activity in Arvinas, Inc.

Institutional investors have also been adjusting their stakes in Arvinas. BlackRock, Inc. reduced its holdings by 524,917 shares to a total of 6,797,584 shares, valued at approximately $72.1 million, reflecting a 7.2% decrease. Meanwhile, Vanguard Portfolio Management LLC opened a new position with 3,889,628 shares worth about $41.2 million. D. E. Shaw & Co., Inc. trimmed its stake by 50,634 shares, ending with 3,638,567 shares valued at nearly $38.6 million.

Arvinas, Inc. Stock Down 3.5%

Arvinas, Inc. is a clinical-stage biotechnology company based in New Haven, Connecticut. The company focuses on developing therapies that degrade disease-causing proteins. As of Saturday, Arvinas had a market cap of approximately $518.1 million and a beta of 1.745, indicating higher volatility relative to the market. The stock's 52-week range is between $6.06 and $14.51, with recent trading around its 50-day moving average of $9.08.

Analysts Set New Price Targets

Analysts have been optimistic about Arvinas, Inc. On June 3, 2026, Stephens & Co. reiterated a 'buy' rating with a price target of $18. Barclays maintained its 'buy' rating on May 13, 2026, with a target of $20. The consensus among analysts is a 'buy' recommendation, with an average price target of $14.8, based on 15 analyst opinions.

About Arvinas, Inc.

Arvinas, Inc. is a biotechnology company engaged in discovering, developing, and commercializing therapies to degrade disease-causing proteins. The company is known for its PROTAC protein degraders, which leverage the body's natural protein disposal system. Arvinas is working on several clinical development programs targeting various diseases, including neurodegenerative diseases and cancers. Founded in 2013, Arvinas collaborates with major pharmaceutical companies such as Pfizer and Bayer.

Bottom Line

Leslie Norwalk's recent purchase of shares in Arvinas, Inc. adds to the notable insider activity at the company. Investors often track such insider transactions for potential insights into the company's prospects. While the 13F filings provide a historical snapshot, they may not represent the current ownership landscape. Analyst ratings and institutional moves can also offer valuable context for understanding market sentiment.